Research

37th ESDR Meeting(European Society for Dermatological Research) Sep 5-8, 2007
Clinical Trial of Gripin® Cream (Maitake Mushroom Extract Cream) for Xerosis Therapy
Mie Nagao1, Shigeru Matsuzaki2, Takashi Sato3, Akira Ito3, and Masao Takahashi1,4
  1. Heimat Co., Ltd., Chuo-ku, Tokyo 103-0027
  2. Yoshii Central Clinic, Tano-gun, Gunma 370-2132
  3. Department of Biochemistry and Molecular Biology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan
  4. Immuno Research Ltd., Auckland, New Zealand

Introduction

Xerosis is defined as dehydration of stratum corneum and characterized by scales, fissures, erosions, and callus in the skin which impairs the skin barrier function. Xerosis is considered to be caused by aging and various environmental factors and is also a common symptom that occurs in chronic skin diseases such as atopic dermatitis. Since patients with xerosis exhibit symptoms, including a scaly and rough skin surface and uncomfortable feeling of itching or pain, effective candidate(s) to structurally and functionally improve the impaired skin barrier may be of benefit to these patients. We have found novel evidence that Grifola frondosa (Maitake mushroom) extract (Gripin®) facilitates the biosynthesis of sebum, which plays an important role in maintaining the skin barrier, in hamsters and humans in vivo and in vitro (POSTER No. 113). In the present study, to clarify whether or not GripinTM may be effective for xerosis, we performed a clinical trial investigation of 0.2% Gripin® cream (舞潤®, MaiJun) (Fig. 1) in the antebrachial and crural of patients with mild to severe xerosis.

Raw materials, OEM and PB option at Heimat Co., Japan Ltd
APCGCT: Asia Pacific Consortium of Gene and Cell Therapy